Competitive antagonists shift the dose-effect curve for an agonist (e.g. the endogenous neurotransmitter) to the right, but this effect can eventually be overcome by enough agonist concentration.
Related content
Non-motor symptoms common in Parkinson’s disease
A table that provides you an overview on non-motor symptoms common in Parkinson’s disease
02.04.2025
Parkinson’s Disease
The Heterogeneity of Depression and Immunometabolic Depression
Professor Dr. Brenda Penninx discusses the heterogeneity of major depressive disorder, with specific reference to immunometabolic depression
31.03.2025
Depression
Parkinson’s Disease – Non-motor Symptom Complex and Comorbidities
In this slide deck, cognitive disorders, mood disorders, quality of life and the comorbidities of PD are discussed
16.03.2025
Parkinson’s Disease